EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Vandana SinghWed, August 19, 2026 at 3:30 PM GMT+3 2 min read
Sunshine Biopharma Inc. (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments.
The newly approved medication, the generic equivalent of the well-known brand Vasotec, will be available to patients in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets.
Sunshine Biopharma currently markets 60 generic prescription drugs in Canada and plans to launch approximately 12 additional drugs during the remainder of 2026.
Read Also:EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Strategic Canadian Distribution
The pharmaceutical firm intends to leverage Nora Pharma Inc., its wholly owned subsidiary operating within Canada.
This dedicated division has already constructed a formidable, wide-reaching distribution infrastructure throughout the nation.
Through this established pipeline, retail pharmacies across Canada can expect to receive their initial shipments of the newly approved generic medication by the close of 2026.
Tapping Into Antihypertensive Market
Sunshine said that, according to industry data, the worldwide antihypertensive drug sector was valued at a robust $25.94 billion in 2025.
Projections indicate this space will surge to an estimated $37.24 billion by the year 2034, registering a steady compound annual growth rate of 4.1%.
Furthermore, the broader Canadian pharmaceutical landscape itself represents approximately 2.1% of the total global industry, proudly standing as the sixth-largest individual market globally.
In May, Sunshine Biopharma received Canadian regulatory approval for generic amoxicillin as part of the expansion of its generic antibiotic portfolio.
The company said the product will be available in multiple dosage forms and strengths and is expected to be ready to ship to pharmacies in August 2026.
In June, the company concluded a one-for-ten reverse stock split to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
SBFM Stock Price Activity: Sunshine Biopharma shares were up 1.79% at $1.13 during premarket trading on Wednesday, according to Benzinga Pro data.
Read Also:Ross Gerber Rips Trump as Oil Soars: Iran Knows He Has 'No Support' Ahead of Midterms
Harrison Jones / USA TODAY NETWORK via Imagn Images
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga:
This article EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug originally appeared on Benzinga.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.